At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNSP CNS Pharmaceuticals, Inc.
Market Closed 12-20 16:00:00 EST
0.1080
-0.0020
-1.82%
盘后0.1124
+0.0044+4.07%
19:59 EST
High0.1200
Low0.1008
Vol4.81M
Open0.1050
D1 Closing0.1100
Amplitude17.45%
Mkt Cap6.21M
Tradable Cap6.09M
Total Shares57.49M
T/O528.01K
T/O Rate8.52%
Tradable Shares56.38M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.